<DOC>
	<DOCNO>NCT02908451</DOCNO>
	<brief_summary>This study define safety profile determine maximum tolerate dose ( MTD ) preliminary efficacy AbGn-107 administer every 28 day ( 4 week ) patient chemo-refractory locally advanced , recurrent metastatic gastric , colorectal pancreatic adenocarcinoma .</brief_summary>
	<brief_title>A Study AbGn-107 Patients With Gastric , Colorectal , Pancreatic Cancer</brief_title>
	<detailed_description>AbGn-107 antibody drug conjugate ( ADC ) target antigen ( AG7 antigen ) present gastric , colorectal , pancreatic cancer . This study standard 3 + 3 dose escalation design cohort expansion . AbGn-107 administered every 28 day patient chemo-refractory locally advanced , recurrent metastatic gastric , colorectal pancreatic adenocarcinoma . The primary objective study define safety profile determine maximum tolerate dose ( MTD ) , secondary objective evaluate pharmacokinetic ( PK ) parameter , immunogenicity , preliminary efficacy .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>1 . Age ≥18 year . A patient may either sex race/ethnicity . 2 . Histologically confirm , chemorefractory , locally advanced , recurrent metastatic gastric ( include GE junction ) , colorectal , pancreatic adenocarcinoma . 1 . Patient must curative option available ( e.g . single metastatic focus liver patient MCRC eligible metastasectomy ) . 2 . Chemorefractory define : Progression follow , intolerant , least one prior line standard systemic therapy advance metastatic gastric pancreatic cancer . Progression follow , intolerant , least two prior line standard systemic therapy advance metastatic colorectal cancer . Patients progressed/recurred follow neoadjuvant/adjuvant chemotherapy earlier stage disease , complete within previous 6 month , eligible . 3 . ( For expansion cohort ) : Tissue must available confirm positive expression AG7 antigen , define proportional score ≥2 , via slide tumor block either original diagnostic biopsy material biopsy relapse disease 4 . Measurable disease RECIST 1.1 criterion 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 . 6 . Adequate organ function within 3 week prior first study drug administration evidence : 1 . Absolute neutrophil count ≥1.5 x 109/L , 2 . Hemoglobin ≥9 g/dL , 3 . Platelet count ≥100 x 109/L , 4 . Serum creatinine ≤1.5 x upper limit normal ( ULN ) calculate creatinine clearance &gt; 60 mL/min , 5 . Total bilirubin &lt; 1.5 x ULN , except patient Gilbert 's disease eligible total bilirubin ≤ 3mg/dL . 6 . Aspartate aminotransferase ( AST ) /serum glutamicoxalacetic transaminase ( SGOT ) alanine aminotransferase ( ALT ) /serum glutamicpyruvic transaminase ( SGPT ) &lt; 2.5 x ULN , , presence document liver metastasis , ≤5 x ULN . 7 . Ability adhere dose visit schedule . 8 . Women childbearing potential ( WOCP ) must negative pregnancy test result prior enrollment . WOCP men whose partner WOCP must agree use highly effective method birth control study 6 month follow last dose study drug . A highly effective method birth control define one result low failure rate ( le 1 % per year ) . 9 . Ability provide write informed consent 10 . Life expectancy least 3 month . 1 . Any persistent , unresolved Common Terminology Criteria Adverse Events ( CTCAE ) Grade ≥2 drugrelated toxicity ( except alopecia , erectile impotence , tinnitus , hot flash , loss libido ) associate previous treatment . Inclusion patient persistent neuropathy hearing loss Grade ≥2 due previous treatment require discussion sponsor . 2 . Radiation therapy within 2 week prior first study drug administration . 3 . Major surgery within 3 week prior first study drug administration . 4 . Any chemotherapy within 30 day enrollment . 5 . Participation clinical study potentially therapeutic agent receipt another investigational product within 21 day 5 plasma halflives , whichever longer , prior first day drug administration ( Day 1 ) . 6 . Active central nervous system metastasis . Patients history brain metastasis may eligible , provide definitively treat clinically stable , discussion sponsor . Treated untreated leptomeningeal disease permit . 7 . Known human immunodeficiency virus ( HIV ) infection know HIVrelated malignancy . Note : HIV test require unless clinical suspicion patient might HIV positive . 8 . Known active hepatitis B C. HBV HCV test require prior Day 1 . 9 . Any clinically significant condition situation , condition study , opinion investigator , would impair ability receive tolerate plan treatment , interfere study evaluation optimal participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Antibody Drug Conjugate</keyword>
	<keyword>AbGn-107</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Gastric</keyword>
	<keyword>Colorectal</keyword>
	<keyword>Pancreatic</keyword>
</DOC>